Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20476168 | 0.82 | IRAK4 (0.32) | — | |
| SCHEMBL4283522 | 0.77 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL3980581 | 0.73 | POLB (0.38) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL4283523 | 0.73 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL6930142 | 0.72 | DRD2 (0.46) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL26631423 | 0.71 | DGAT1 (0.33) | — | |
| Hydrochloric Acid SCHEMBL31352065 | 0.71 | POLB (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL23938200 | 0.68 | DRD2 (0.46) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL13603599 | 0.68 | DRD2 (0.46) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL13564548 | 0.68 | DRD2 (0.46) | DRD2DRD4DRD3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079880-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079878-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079879-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| US-12497366-B2 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4638442-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | disclosed |
| US-20250326722-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| EP-4588914-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
| WO-2022063784-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | US | disclosed |
| CN-108290838-B | Biaryl derivatives and drugs containing the same | 科研制药株式会社 | 2021-12-31 | — | — | CN | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| WO-2021023813-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-02-11 | — | — | WO | disclosed |
| WO-2020263967-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
| WO-2012052451-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647675-B2 | Biaryl derivative and medicine containing same | MAN2B1, CBR3, MANBA | DRD2 1336/4885DRD4 1483/4885DRD3 667/4885 |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | MAN2B1, CBR3, MANBA | DRD2 1336/4885DRD4 1483/4885DRD3 667/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | DRD2 4467/4885DRD4 4624/4885DRD3 4307/4885 |
| US-20220089538-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | DRD2 1079/4885DRD4 1764/4885DRD3 617/4885 |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NPR1, CBR1, NAT1 | DRD2 1625/4885DRD4 2639/4885DRD3 1617/4885 |
| US-12497366-B2 | Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof | WEE1, WEE2, NOS1 | DRD2 3807/4885DRD4 4120/4885DRD3 4332/4885 |
| US-20250326722-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, NOS1 | DRD2 3807/4885DRD4 4120/4885DRD3 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.